Pharmaceuticals, Biotechnology and Life Sciences
BEIJING–(BUSINESS WIRE)–Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient…
Inauguration Ceremony Highlights World-Class, Comprehensive Drug Development Capabilities and More Than Two Decades of Growth in China BURLINGTON, N.C.–(BUSINESS WIRE)–LabCorp®…
FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)–MicuRx Pharmaceuticals, Inc., today announced positive top-line results for study MRX4-201, a US Phase 2…
Trovagene will present new clinical data from its Phase 2 trial of onvansertib, in combination with Zytiga (abiraterone acetate)/prednisone, in…
DelMar Pharmaceuticals said Tuesday that 17 of the first 20 enrolled patients have received at least their first assessment, and nine have been assessed as having achieved a complete response (CR) (9/17, or 53%), seven have been assessed with stable disease (SD), (7/17, or 41%), while nine has been assessed as disease progression (PD) (1/17, or 6%).
Inovio Pharmaceuticals published its positive results from the first-in-human trial of its vaccine against the Middle East Respiratory Syndrome Coronavirus…
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
JNDA Submission Represents First Regulatory Submission for Marketing Approval of Vadadustat CAMBRIDGE, Mass.–(BUSINESS WIRE)–Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced…
Sinomed has completed enrollment in the PIONEER III randomized, controlled clinical trial testing the BuMA Supreme DES and support U.S. and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.
Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.1